- Interim data from an investigator-initiated study in first-line maintenance setting for advanced pancreatic cancer suggest that Rubraca provides disease control with no new safety signals in 19 evaluable platinum-sensitive patients with germline BRCA1, germline or somatic BRCA2, or germline PALB2 mutations
- Clovis is evaluating a potential clinical and regulatory path forward for Rubraca in pancreatic cancer
- Nonclinical studies of rucaparib and lucitanib in multiple solid tumor types and Rubraca Trials in Progress posters also presented at AACR 2019
Tuesday, April 2, 2019
Clovis: Interim Results of Rubraca® (rucaparib) Phase 2 in Pancreatic Cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.